Greg Roumeliotis, MSc, Orgenesis, Germantown, MD, comments on the importance of automation in point-of-care manufacturing. Collaboration with startups, manufacturers and Orgenesis Mobile Production Units and Labs (OMPULs) has accelerated the point-of-care production and commercialization of advanced therapies. OMPULs operate in a decentralized system with partially centralized aspects, allowing efficient delivery of products. He additionally highlights the need for good manufacturing practice (GMP) readiness, as well as training programs developed by Orgenesis to further advance the cell and gene therapy industry. This interview took place at Advanced Therapies Week 2022.
Greg Roumeliotis, MSc is an employee of Orgenesis.